Literature DB >> 17667938

Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.

C Scavelli1, B Nico, T Cirulli, R Ria, G Di Pietro, D Mangieri, A Bacigalupo, G Mangialardi, A M L Coluccia, T Caravita, S Molica, D Ribatti, F Dammacco, A Vacca.   

Abstract

Bone marrow macrophages of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies of undetermined significance (MGUS) and benign anemia (controls) were stimulated for 7 days with vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and analysed for the expression of endothelial cell (EC) markers by reverse transcription (RT)-PCR, real-time RT-PCR, western blot and immunofluorescence. Their vasculogenic ability was investigated in vitro in a Matrigel assay and in vivo on bone marrow biopsies through dual immunofluorescence and confocal laser microscopy. Active MM macrophages exposed to VEGF and bFGF acquired EC markers and formed capillary-like structures mimicking paired bone marrow ECs (multiple myeloma patient-derived endothelial cells, MMECs), with major responsiveness compared to macrophages from nonactive MM, MGUS or controls. Bone marrow biopsies of active MM harbored 'mosaic' vessels, being formed by MMECs, EC-like macrophages and macrophages themselves. These figures were rare in nonactive MM and absent in MGUS or controls. Our data indicate that macrophages contribute to build neovessels in active MM through vasculogenic mimicry, and this ability proceeds parallel to progression of the plasma cell tumors. Macrophages may be a target for the MM antivascular treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17667938     DOI: 10.1038/sj.onc.1210691

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

Review 1.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy.

Authors:  Bingxue Shang; Gaochuan Zhang; Yanyan Pan; Quansheng Zhou
Journal:  Cancer Microenviron       Date:  2012-05-17

3.  A Matrigel-based tube formation assay to assess the vasculogenic activity of tumor cells.

Authors:  Ralph A Francescone; Michael Faibish; Rong Shao
Journal:  J Vis Exp       Date:  2011-09-07       Impact factor: 1.355

4.  Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma.

Authors:  S Panchabhai; K Kelemen; G Ahmann; S Sebastian; J Mantei; R Fonseca
Journal:  Leukemia       Date:  2015-07-23       Impact factor: 11.528

Review 5.  Macrophages in multiple myeloma: key roles and therapeutic strategies.

Authors:  Khatora S Opperman; Kate Vandyke; Peter J Psaltis; Jacqueline E Noll; Andrew C W Zannettino
Journal:  Cancer Metastasis Rev       Date:  2021-01-06       Impact factor: 9.264

Review 6.  Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors:  Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 15.470

7.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

Review 8.  Monocyte subpopulations in angiogenesis.

Authors:  Heather J Dalton; Guillermo N Armaiz-Pena; Vianey Gonzalez-Villasana; Gabriel Lopez-Berestein; Menashe Bar-Eli; Anil K Sood
Journal:  Cancer Res       Date:  2014-02-20       Impact factor: 12.701

Review 9.  Targeting cancer stem cells to modulate alternative vascularization mechanisms.

Authors:  Elena Monzani; Caterina Am La Porta
Journal:  Stem Cell Rev       Date:  2008       Impact factor: 5.739

10.  Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.

Authors:  Heather J Dalton; Sunila Pradeep; Michael McGuire; Yared Hailemichael; Shaolin Ma; Yasmin Lyons; Guillermo N Armaiz-Pena; Rebecca A Previs; Jean Marie Hansen; Rajesha Rupaimoole; Vianey Gonzalez-Villasana; Min Soon Cho; Sherry Y Wu; Lingegowda S Mangala; Nicholas B Jennings; Wei Hu; Robert Langley; Hong Mu; Michael Andreeff; Menashe Bar-Eli; Willem Overwijk; Prahlad Ram; Gabriel Lopez-Berestein; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2017-08-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.